PROMOMED is the new sales leader in the GLP-1 drug market in Russia

PROMOMED Group of Companies has become the new sales leader of GLP‑1 class drugs in the Russian market. According to AlphaRM's retail audit, in the first eight weeks of 2026 (W1–W8), the GLP‑1 segment recorded a change of leaders in both molecules and companies in value terms. The first place among the molecules was taken by tyrzepatide with a share of 65.1% versus 34.5% for semaglutide, and the share of PROMOMED in segment sales was 51.9%.

Leadership in such a dynamically growing therapeutic class is the result of PROMMED's systematic work to develop its portfolio, ensure stable supplies and increase the availability of modern solutions for the treatment of type 2 diabetes and body weight control. In 2023, PROMOMED released a domestic semaglutide under the trade name of Quincenta®. Later, the line was expanded with such blockbusters as Velgia® and a drug in disposable Velgia® Ivf injectors. In 2025, PROMOMED launched the innovative production of tyrzepatide in disposable autoinjectors without preservatives under the trade name Tirzetta®. The figures confirm the demand for this molecule and such a technological solution among Russian patients and specialists: over the past year, the drug has become the second largest in absolute sales growth among the entire retail segment of the Russian market.

The Company's priority is to provide patients throughout the country with modern and affordable therapy, and doctors with a wide range of evidence—based solutions. PROMOMED consistently invests in the development of a portfolio in the field of metabolic diseases, expands the range of dosages and forms of release, and strengthens educational and service programs for the professional community.

Background information
The analysis was performed for the EphMRA A10S group (GLP‑1 receptor agonists) based on monitoring retail sales of AlphaRM drugs, period W1–W8 2026, in value terms. Source: Retail audit and monitoring of sales of medicines and dietary supplements in the Russian Federation, AlphaRM.

In 2025, PROMOMED's revenue in the Endocrinology market segment increased by 163% YoY and amounted to 21.6 billion rubles. At the same time, the relevant market of drugs for diabetes and obesity has grown by 101% over this period , to 46 billion rubles.